DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
Clinical trials for DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) explained in plain language.
Never miss a new study
Get alerted when new DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) trials appear
Sign up with your email to follow new studies for DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Could an arthritis drug boost lymphoma treatment?
Disease control Not yet recruitingThis study tests whether adding the anti-inflammatory drug celecoxib to standard chemotherapy (R-CHOP) works better than R-CHOP alone for people with a hard-to-treat type of lymphoma called CD5-positive diffuse large B-cell lymphoma. About 60 adults with newly diagnosed advanced …
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated May 17, 2026 07:00 UTC
-
New drug combo aims to boost lymphoma treatment
Disease control Not yet recruitingThis study tests a new drug, epcoritamab, added to standard chemotherapy (R-CHOP) for people newly diagnosed with an aggressive form of B-cell lymphoma. The main goal is to check for a specific side effect called cytokine release syndrome. About 20 adults will take part in this e…
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
Phase: PHASE2 • Sponsor: Mwanasha Merrill, MD • Aim: Disease control
Last updated May 17, 2026 06:52 UTC
-
New hope for lymphoma patients: experimental drug combo enters trials
Disease control Not yet recruitingThis study tests whether adding the experimental drug lisatoclax to standard chemotherapy (R-CHOP or Pola-R-CHP) can safely improve outcomes for people with untreated diffuse large B-cell lymphoma (DLBCL). About 122 adults aged 18-70 will participate. The goal is to see if the co…
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
Phase: PHASE1, PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated May 17, 2026 06:51 UTC
-
Experimental Dual-Targeting cell therapy takes on tough lymphomas
Disease control Not yet recruitingThis early study tests a new type of immune cell therapy (bispecific AbTCR-T cells) in 3 adults with B-cell lymphoma that has not responded to or returned after at least two prior treatments. The cells are designed to recognize and attack two cancer markers (CD19 and CD22) at onc…
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
Phase: EARLY_PHASE1 • Sponsor: First Affiliated Hospital Xi'an Jiaotong University • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
Can radiation and an antibiotic make CAR-T therapy safer and more effective?
Disease control Not yet recruitingThis early-stage trial tests whether giving radiation therapy and the antibiotic vancomycin before standard CAR-T cell treatment is safe and doable for people with large B-cell lymphoma. About 14 adults whose lymphoma has come back or not responded to treatment will take part. Th…
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
Phase: PHASE1 • Sponsor: Abramson Cancer Center at Penn Medicine • Aim: Disease control
Last updated May 14, 2026 12:02 UTC
-
New drug targets hard-to-treat cancers with missing gene
Disease control Not yet recruitingThis early-phase study tests a new drug called CS08399 in people with advanced solid tumors or lymphoma that have a specific genetic deletion (MTAP). The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. About 186 adults who have run out of …
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
Phase: PHASE1 • Sponsor: Chipscreen Biosciences, Ltd. • Aim: Disease control
Last updated May 14, 2026 12:01 UTC
-
Colombia launches first CAR-T trial for Hard-to-Treat blood cancers
Disease control Not yet recruitingThis study aims to bring CAR-T cell therapy to Colombia for people with certain blood cancers that have come back or not responded to treatment. It has two parts: first, setting up the necessary partnerships and facilities to produce the therapy locally, and second, a small trial…
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
Phase: NA • Sponsor: GUSTAVO SALGUERO • Aim: Disease control
Last updated May 13, 2026 15:59 UTC
-
New hope for elderly lymphoma patients: targeted drug duo plus chemo
Disease control Not yet recruitingThis study tests whether adding two targeted drugs (mosunetuzumab and polatuzumab vedotin) to a standard chemotherapy backbone can help older adults (70+) with a newly diagnosed, aggressive type of lymphoma called diffuse large B-cell lymphoma. About 31 participants will receive …
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
Phase: PHASE2 • Sponsor: Medical College of Wisconsin • Aim: Disease control
Last updated May 11, 2026 20:48 UTC
-
What happens when a key lymphoma drug stops working? new study aims to find out
Knowledge-focused Not yet recruitingThis study looks at what treatments work best for people with diffuse large B-cell lymphoma (DLBCL) after a drug called polatuzumab vedotin stops working. Researchers will track 200 patients to see which salvage therapies lead to the best outcomes. The goal is to gather real-worl…
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
Sponsor: Peking Union Medical College Hospital • Aim: Knowledge-focused
Last updated May 12, 2026 13:40 UTC
-
New study tracks brain health after CAR-T therapy
Knowledge-focused Not yet recruitingThis study follows 100 adults with certain types of lymphoma who are receiving CAR-T cell therapy. Researchers will test thinking, memory, and quality of life before treatment and again at 6, 12, and 24 months after. The goal is to understand how the therapy affects brain functio…
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
Sponsor: Fondazione Italiana Linfomi - ETS • Aim: Knowledge-focused
Last updated May 04, 2026 16:24 UTC